Trends in Diabetes, Obesity and Metabolism

Open access

Research Article

Role of Red Blood Cell Transfusion in the Management of Acute Painful Episodes in Sickle Cell Disease

Tamer A Addissouky* _

American Society for Clinical Pathology (ASCP), Chicago, USA

***Correspondence**: Tamer A Addissouky, American Society for Clinical Pathology (ASCP), Chicago, USA, E-mail: tedesoky@gmail.com, DOI: 10.1042/TDOM.1.1.0001

Abstract

Sickle cell disease (SCD) is a hereditary hemoglobin disorder characterized by chronic hemolysis, vascular injury, and recurrent vaso-occlusive events. Acute painful crises are among the most common and debilitating complications experienced by affected individuals. These episodes result from the obstruction of microvascular circulation by rigid and poorly deformable red blood cells, leading to tissue ischemia and inflammation. Recent evidence suggests that red blood cell (RBC) transfusion may play an important role in reducing the severity of painful crises by decreasing the proportion of sickled erythrocytes in circulation and improving tissue oxygen delivery. This review discusses the pathophysiological basis of painful crises in SCD and examines the potential therapeutic benefits of RBC transfusion during severe episodes.

Keywords: Sickle cell diseases, Acute painful crises, Hardened red blood cells, Capillary endothelial inflammation, Capillary endothelial edema

Received date: Jan 2, 2025; **Accepted date:** Jan 01, 2025; **Published date:** Jan 29, 2025

Citation: Tamer A Addissouky (2025) Role of Red Blood Cell Transfusion in the Management of Acute Painful Episodes in Sickle Cell Disease. RMB, 1: 1

Introduction

Sickle cell disease is a chronic multisystem disorder caused by the inheritance of abnormal hemoglobin S. Under conditions such as hypoxia, infection, dehydration, or physiological stress, red blood cells undergo structural changes that reduce their flexibility and increase their tendency to obstruct small blood vessels. The resulting impairment in blood flow triggers tissue hypoxia, inflammation, and pain.

Painful vaso-occlusive crises represent the hallmark clinical manifestation of SCD. These episodes vary in intensity and duration and frequently require hospitalization. Recurrent crises contribute to cumulative organ damage, reduced quality of life, and increased mortality risk. Consequently, effective management strategies are essential for improving long-term outcomes.

Pathophysiology of acute painful crises

The development of painful crises involves a complex interaction between abnormal erythrocytes, endothelial dysfunction, inflammatory mediators, and altered blood rheology. Sickled red blood cells become rigid and adhesive, promoting their interaction with vascular endothelial cells and circulating leukocytes.

As microvascular obstruction progresses, oxygen delivery to tissues decreases significantly. Ischemia initiates inflammatory cascades that further worsen vascular dysfunction. The resulting cycle of hypoxia, inflammation, and vascular occlusion contributes directly to the severe pain experienced during crises.

Repeated vaso-occlusive episodes may also cause permanent vascular injury and progressive organ dysfunction involving the lungs, kidneys, liver, brain, and cardiovascular system.

Clinical impact of painful crises

Painful crises are the leading cause of emergency department visits and hospital admissions among patients with SCD. Although pain itself may not always be fatal, the underlying pathophysiological processes associated with a crisis can precipitate life-threatening complications.

Episodes are frequently triggered by infections, surgical conditions, emotional stress, or other factors that increase metabolic demands. During these circumstances, oxygen requirements rise while vascular perfusion becomes increasingly compromised. This imbalance can accelerate sickling and worsen tissue injury.

Frequent crises are associated with a higher burden of chronic complications, including stroke, pulmonary disease, chronic kidney disease, leg ulcers, and cardiovascular abnormalities.

Therapeutic role of red blood cell transfusion

Red blood cell transfusion is an important supportive intervention in selected patients with SCD. By increasing the proportion of normal erythrocytes and reducing the concentration of sickled cells, transfusion improves oxygen-carrying capacity and enhances tissue perfusion.

Improved circulation may reduce ongoing vaso-occlusion and interrupt the cycle of ischemia and inflammation responsible for severe pain. Many clinicians observe a reduction in pain severity following transfusion in patients experiencing acute crises.

In addition to pain relief, transfusion may decrease the risk of serious complications such as acute chest syndrome, stroke, and multiorgan dysfunction in appropriately selected patients.

Potential advantages of transfusion during severe crises

Several mechanisms may explain the clinical benefits associated with RBC transfusion:

- Increased oxygen delivery to hypoxic tissues.
- Reduction in the proportion of sickled erythrocytes.
- Improvement in blood flow through the microcirculation.
- Decreased endothelial injury and inflammation.
- Prevention of progressive organ damage.

These effects collectively contribute to clinical stabilization during severe vaso-occlusive events.

Limitations and risks

Despite its benefits, transfusion therapy is not without risk. Repeated transfusions can lead to alloimmunization, iron overload, transfusion reactions, and difficulties in obtaining compatible blood products.

The development of antibodies against donor blood groups may complicate future transfusions. Therefore, transfusion should be reserved for carefully selected situations in which expected benefits outweigh potential risks.

Long-term disease-modifying therapies, including hydroxyurea and newer targeted treatments, remain essential components of comprehensive disease management.

Future perspectives

Advances in transfusion medicine, genetic therapies, and novel pharmacological agents may further improve outcomes for patients with SCD. Future research should focus on identifying patients most likely to benefit from transfusion therapy and establishing standardized protocols for acute painful crises.

Large prospective clinical studies are needed to clarify the optimal timing, frequency, and type of transfusion interventions in different clinical settings.

Conclusion

Acute painful crises remain one of the most serious complications of sickle cell disease. These episodes arise from microvascular obstruction, tissue hypoxia, and systemic inflammation caused by abnormal red blood cells. Red blood cell transfusion appears to provide important clinical benefits by improving oxygen delivery and reducing the burden of sickled erythrocytes. While transfusion is associated with certain risks, it remains a valuable therapeutic option in severe crises and may contribute to pain reduction, prevention of organ damage, and improved patient outcomes when used appropriately.

References

1) Kaltsas A. Cystic Fibrosis and male infertility: from genetics to future perspectives in assisted reproductive technologies. Genes. 2025, 16:994.
2) Amaral MD, Pankonien I. Cystic Fibrosis as a paradigmatic disease in bringing science to the bedside. FEBS Lett. 2025, 8:1-12.
3) Závoti O, Csanády L. Molecular and pharmacological evaluation of rare, cystic fibrosis-causing missense mutations of the CFTR channel. J Physiol. 2025, 1:1-17.
4) Vermaut A, Geudens V, Willems L, Aerts G, Kerckhof P, et al. Airway remodeling in cystic fibrosis is heterogeneous. Ann Am Thorac Soc. 2024, 22:523-532.
5) Yıldız CA, Gökdemir Y, Eralp EE, Ergenekon P, Karakoç F, et al. Cystic fibrosis treatment landscape: progress, challenges, and future directions. Turk Arch Pediatr. 2025, 60:117-125.
6) Dobra R, Carroll S, Davies JC, Dowdall F, Duff A, et al. Exploring the complexity of Cystic Fibrosis (CF) and psychosocial wellbeing in the 2020s: current and future challenges. Paediatr Respir Rev. 2024, 54:35-42.
7) Tümmler B, Pallenberg ST, Dittrich AM, Graeber SY, Naehrlich L, et al. Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators. Mol Cell Pediatr. 2025, 12:6.
8) Addissouky TA, El Tantawy El Sayed IE, Ali MMA. Emerging biomarkers for precision diagnosis and personalized treatment of cystic fibrosis. J Rare Dis. 2024, 3:28.
9) Fabro AT, Brcic L, Achcar RD. Editorial: biomarkers for progressive pulmonary fibrosis. Front Med. 2025, 12:1595959.
10) Caterino M, Costanzo M, Castaldo A, Iacotucci, P, Carnovale V, et al. Metabolomic profiling of saliva from cystic fibrosis patients. Sci Rep. 2025, 15:479.
11) Shao M, Li C, Li J, Chen R, Wang Y, et al. NSUN2 Promotes PM2.5-Induced epithelial-mesenchymal transition through methylating chitinase 3-Like-1 mRNA. J Hazard Mater. 2025, 495:138883.
12) Bi Z, Wang X, Liu X. ITGAV, a specific biomarker associated with the pathogenesis of idiopathic pulmonary fibrosis. Sci Rep. 2025, 15:1-16.